Table 2 Lipid and plasma fatty acid characteristics of the study participants

Total-C (mmol/L)

Control

5.02 ± 0.2

5.06 ± 0.2

Treatment

4.22 ± 2.3

4.21 ± 2.2

LDL-C (mmol/L)

Control

3.13 ± 0.2

3.10 ± 0.2

Treatment

2.42 ± 2.2

2.44 ± 2.3

HDL-C (mmol/L)

Control

1.39 ± 0.1

1.46 ± 0.1

Treatment

1.34 ± 0.6

1.35 ± 0.7

VLDL-C (mmol/L)

Control

0.50 ± 0.0

0.51 ± 0.1

Treatment

0.46 ± 0.7

0.42 ± 0.6

Triacylglycerols (mmol/L)^a

Control

1.01 ± 0.1

1.10 ± 0.3

Treatment

1.02 ± 0.2

0.91 ± 0.1 ^{b, c}

Pre-treatment

Post-treatment

ALA (u mol/L)

Control

22.61 ± 3.4

20.22 ± 2.1

Treatment

23.18 ± 2.3

19.74 ± 1.7

AA (u mol/L)

Control

670.74 ± 60.1

696.77 ± 87.1

Treatment

599.91 ± 33.9

613.12 ± 27.0

DHA (u mol/L)^a

Control

83.23 ± 10.3

103.23 ± 15.0

Treatment

91.18 ± 9.7

125.58 ± 11.9 ^{b, c}

EPA (u mol/L)

Control

22.49 ± 3.4

20.59 ± 6.8

Treatment

17.93 ± 3.1

20.77 ± 2.9